HRP20190917T1 - NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE - Google Patents

NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE Download PDF

Info

Publication number
HRP20190917T1
HRP20190917T1 HRP20190917TT HRP20190917T HRP20190917T1 HR P20190917 T1 HRP20190917 T1 HR P20190917T1 HR P20190917T T HRP20190917T T HR P20190917TT HR P20190917 T HRP20190917 T HR P20190917T HR P20190917 T1 HRP20190917 T1 HR P20190917T1
Authority
HR
Croatia
Prior art keywords
cdr
seq
sequence given
heavy chain
light chain
Prior art date
Application number
HRP20190917TT
Other languages
English (en)
Croatian (hr)
Inventor
David Paul Humphreys
Daniel John Lightwood
Kerry Louise Tyson
David Edward Ormonde KNIGHT
Karine Jeannine Madeleine HERVÉ
Joanne Elizabeth COMPSON
Matthew Jon Timothy PAGE
Andrew Charles Payne
Nicola Louise FISHER
Brendon MACKENZIE
Matthew Cox
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190917(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of HRP20190917T1 publication Critical patent/HRP20190917T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20190917TT 2011-09-16 2012-09-10 NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE HRP20190917T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US201261638731P 2012-04-26 2012-04-26
PCT/GB2012/052222 WO2013038156A1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP12761789.2A EP2758432B1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile

Publications (1)

Publication Number Publication Date
HRP20190917T1 true HRP20190917T1 (hr) 2019-07-26

Family

ID=46881094

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190917TT HRP20190917T1 (hr) 2011-09-16 2012-09-10 NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE

Country Status (30)

Country Link
US (2) US10752676B2 (enExample)
EP (2) EP3617227A3 (enExample)
JP (3) JP6152107B2 (enExample)
KR (1) KR20140063825A (enExample)
CN (2) CN108424449A (enExample)
AU (1) AU2012307157B2 (enExample)
BR (1) BR112014006175B1 (enExample)
CA (1) CA2848611A1 (enExample)
CL (1) CL2014000491A1 (enExample)
CO (1) CO6930310A2 (enExample)
CY (1) CY1121673T1 (enExample)
DK (1) DK2758432T3 (enExample)
EA (1) EA032475B1 (enExample)
EC (1) ECSP14013316A (enExample)
ES (1) ES2729278T3 (enExample)
HK (1) HK1199463A1 (enExample)
HR (1) HRP20190917T1 (enExample)
HU (1) HUE043661T2 (enExample)
IL (1) IL231167A0 (enExample)
LT (1) LT2758432T (enExample)
MX (1) MX2014002769A (enExample)
PE (1) PE20141547A1 (enExample)
PH (1) PH12014500456A1 (enExample)
PL (1) PL2758432T3 (enExample)
PT (1) PT2758432T (enExample)
SG (2) SG10201701055WA (enExample)
SI (1) SI2758432T1 (enExample)
TN (1) TN2014000101A1 (enExample)
WO (1) WO2013038156A1 (enExample)
ZA (1) ZA201402760B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012307157B2 (en) * 2011-09-16 2017-08-03 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile
EP2925362A4 (en) * 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
US10226523B2 (en) * 2013-04-22 2019-03-12 The Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
US9926345B2 (en) 2014-02-18 2018-03-27 The Hospital For Sick Children Compositions and methods for treating or preventing Clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
WO2016168392A1 (en) * 2015-04-15 2016-10-20 Medimmune, Llc Methods for treating clostridium difficile infection and associated disease
EP4074730A1 (en) 2015-06-24 2022-10-19 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies with tailored affinity
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AR106230A1 (es) 2015-10-02 2017-12-27 Hoffmann La Roche Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
WO2018111662A1 (en) * 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Human genetic markers associated with response to treatments that target clostridium difficile toxin b
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
SK117395A3 (en) 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
ATE195740T1 (de) 1993-11-17 2000-09-15 Om Pharma Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
JP5220248B2 (ja) 1997-08-29 2013-06-26 アンチジェニックス・インコーポレイテッド アジュバントｑｓ−２１および賦形剤としてポリソルベートまたはシクロデキストリンを含む組成物
DE69815692T2 (de) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
DK1567117T3 (da) * 2002-11-26 2012-05-21 Univ Chicago Forebyggelse og behandling af mikrobe-medierede epitelsygdomme
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
BRPI0517592B1 (pt) 2004-12-27 2016-03-15 Huntsman Corp Australia Pty Ltd formulação agroquímica sólida, método para preparar a mesma, e, formulação de concentração de suspensão
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US8852600B2 (en) * 2006-06-08 2014-10-07 The Rockefeller University Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
CN101842387B (zh) * 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
CN101980723A (zh) * 2008-02-28 2011-02-23 3M创新有限公司 艰难梭菌芽孢的抗体及其用途
ES2793008T3 (es) * 2008-06-25 2020-11-12 Novartis Ag Anticuerpos estables y solubles que inhiben VEGF
JP6063122B2 (ja) 2008-09-26 2017-01-18 ユセベ ファルマ ソシエテ アノニム 生物学的産物
EP2405940B1 (en) * 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
ES2757675T3 (es) * 2010-04-15 2020-04-29 Progenics Pharm Inc Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile
WO2012055030A1 (en) * 2010-10-25 2012-05-03 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
AU2012307157B2 (en) * 2011-09-16 2017-08-03 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US20150259402A1 (en) * 2012-10-19 2015-09-17 Evec Inc. Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Also Published As

Publication number Publication date
US10752676B2 (en) 2020-08-25
BR112014006175B1 (pt) 2020-02-11
JP6152107B2 (ja) 2017-06-21
JP2017149773A (ja) 2017-08-31
HK1199463A1 (en) 2015-07-03
JP2020037555A (ja) 2020-03-12
CA2848611A1 (en) 2013-03-21
TN2014000101A1 (en) 2015-07-01
EA032475B1 (ru) 2019-06-28
ZA201402760B (en) 2016-03-30
US20140348844A1 (en) 2014-11-27
EP2758432B1 (en) 2019-03-06
ECSP14013316A (es) 2014-08-29
SG11201400193SA (en) 2014-05-29
SI2758432T1 (sl) 2019-07-31
CN103958544A (zh) 2014-07-30
HUE043661T2 (hu) 2019-08-28
IL231167A0 (en) 2014-04-30
PT2758432T (pt) 2019-06-14
PL2758432T3 (pl) 2019-08-30
NZ623293A (en) 2016-05-27
AU2012307157A1 (en) 2014-04-24
ES2729278T3 (es) 2019-10-31
JP6603685B2 (ja) 2019-11-06
SG10201701055WA (en) 2017-03-30
CN108424449A (zh) 2018-08-21
CL2014000491A1 (es) 2014-12-26
AU2012307157B2 (en) 2017-08-03
EA201400345A1 (ru) 2014-09-30
EP3617227A2 (en) 2020-03-04
PH12014500456A1 (en) 2014-04-14
EP3617227A3 (en) 2020-06-03
WO2013038156A1 (en) 2013-03-21
MX2014002769A (es) 2014-06-11
CO6930310A2 (es) 2014-04-28
US20200377578A1 (en) 2020-12-03
DK2758432T3 (da) 2019-06-03
PE20141547A1 (es) 2014-10-25
KR20140063825A (ko) 2014-05-27
CN103958544B (zh) 2018-04-24
CY1121673T1 (el) 2020-07-31
EP2758432A1 (en) 2014-07-30
BR112014006175A2 (pt) 2017-04-04
JP2015501286A (ja) 2015-01-15
LT2758432T (lt) 2019-06-10

Similar Documents

Publication Publication Date Title
HRP20190917T1 (hr) NEUTRALIZIRAJUĆA PROTUTIJELA NA GLAVNE EKSOTOKSINE TcdA i TcdB CLOSTRIDIUM DIFFICILE
JP2020037555A5 (enExample)
CL2013003373A1 (es) Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll).
CO2018004532A2 (es) Anticuerpos anti-cd19 humano con alta afinidad
UA108466C2 (en) Antibody antagonises c-Met
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
RU2020129387A (ru) Антитела к pd-1 собак
NZ596837A (en) Anti-vegf antibodies and their uses
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени
RU2018106456A (ru) Антитело к epha4
PE20220279A1 (es) Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos
MX2018014714A (es) Composiciones para inhibir la activacion del complemento dependiente de la masp-2.
NZ618067A (en) Anti-cd100 antibodies and methods for using the same
MY186351A (en) Multispecific antibodies
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
NZ605980A (en) Anti-fap antibodies and methods of use
NZ705653A (en) Novel antibody for the diagnosis and/or prognosis of cancer
HRP20211444T1 (hr) Anti-dll3 antitijelo
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
RU2016100892A (ru) Антитела против tweakr и их применение
AR080243A1 (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
RU2017128882A (ru) Антитела к биотину и способы их применения
NZ603182A (en) Humanized anti cxcr4 antibodies for the treatment of cancer